Anthony Clare


Anthony advises on a wide range of corporate matters including M&A (public and private), joint ventures and equity capital markets. He has acted on over 20 IPOs in the London market, and a number of high profile cross-border public M&A mandates.

Anthony is named as a 'star' in the corporate section of the 2015 edition of LMG Life Sciences and is listed in the Top 50 European M&A lawyers 2014 by Global M&A Network (EMEA). He has been ranked in Chambers for the last three years as a leading individual for M&A: High End Capability.

Anthony has served for over nine years on the board, and as Vice Chairman, of The Babraham Institute, Cambridge, a leading European bioscience research institute.

Anthony’s life sciences experience includes advising:

  • e-therapeutics on its £22.5 million fundraise. Based in Oxford, UK, e-therapeutics aims to transform the drug discovery process by leveraging its computational power and biological expertise to accelerate the path to identifying and developing effective therapies.
  • Acacia Pharma Group plc, a pharmaceutical company specialising in the development of drugs for cancer and post-operative supportive care, on its Euronext Brussels IPO, and prior to that on its Series A, B and C investment rounds to fund development of its two lead products.
  • Silence Therapeutics plc on its acquisition by way of reverse takeover of Palo Alto-based Intradigm Corporation, and the associated £15 million equity fundraising through a placing, to create a leading company in the field of RNA interference (RNAi).
  • Ark Therapeutics Group plc on its acquisition of Helsinki-based Lymphatix Oy giving Ark Therapeutics royalty-free exploitation rights to the vascular endothelial growth factor genes known as VEGF-D and VEGF-C, complementing its existing portfolio of VEGF-based programmes.
  • UCB Biopharma on various strategic investments alongside financial investors in various early stage portfolio companies, in both the US and throughout Europe.
  • Ark Therapeutics Group plc in relation to two placings and open offers of shares raising, respectively, £37.4 million and £27.1 million, and on its original flotation on the London Stock Exchange.
  • NeuTec Pharma Plc on its £305.1 million recommended cash takeover by Novartis.
  • SR Pharma plc on its £8.3 million placing of new shares with institutional investors and the £1.7 million equity investment in the company by Nasdaq-listed biotech company Introgen Therapeutics Inc., following its acquisition of Atugen AG.
  • Arakis Limited on a £29 million private funding round.
  • Arakis Limited and its shareholders on the acquisition of Arakis by Sosei Co. Ltd., a leading Japanese biopharmaceutical company, creating a global biopharmaceutical company with an implied value of £278 million.
  • Quadrant Technologies Limited on its £46.7 million sale to ML Laboratories plc.
  • Cambridge Antibody Technology plc in connection with a £75 million subscription by AstraZeneca of a 19.9 per cent equity stake.
  • Inion Oy, Quadrant Healthcare and Ark Therapeutics on their London Stock Exchange listings.
  • Quadrant Technologies Limited on its acquisition from Elan Corporation, plc of the UK-based drug delivery business Elan Drug Delivery Limited (EDD-UK).
  • NM Rothschild, JP Morgan Cazenove and Peel Hunt as the sponsor and joint bookrunners on a Class 2 acquisition and related placing by Vectura plc.

He advises on M&A and equity capital markets transactions involving life sciences businesses and is 'very knowledgeable and responsive'

Chambers UK 2018